ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials

Dow Jones

01/14

By Amira McKee

Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients.

The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks.

The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells.

In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer.

ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 13, 2026 16:09 ET (21:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603630005"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603630005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603630005?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603630005","market":"hk","top_or_hot":-1,"title":"ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n</p>\n<p>\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n</p>\n<p>\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n</p>\n<p>\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n</p>\n<p>\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 05:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n</p>\n<p>\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n</p>\n<p>\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n</p>\n<p>\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n</p>\n<p>\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603630005","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603630005","pubTimestamp":1768338540,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients.The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks.The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells.In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer.ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio股价因肺癌药物试验取得积极结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n\n\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n\n\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n\n\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n\n\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 16:09 ET (21:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}